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Based on American Diabetes Association (ADA), diabetes can be classified into the following general categories: type 1 
diabetes (T1D), type 2 diabetes (T2D), gestational diabetes mellitus (GDM) and specific types of diabetes due to other 
cause. Obesity is by far the main underlying factor causing T2D and its pathological potential lies in obesity-associated 
insulin resistance, activation of innate immunity and chronic low-grade inflammation. When tissue inflammation induced, 
tissue destruction occurs, 'self' antigens, which are generally not accessible to T cells, can be released from the affected 
tissues and promote autoimmune activation. The 4 major autoantibodies are islet-cell cytoplasmic autoantibodies (ICA), 
glutamid acid decarboxylase antibody (GADA), islet antigen-2 antibody (IA-2A) and insulin autoantibodies (IAA). In addition, 
ZnT8A has recently been found to predict T1D. ZnT8 is contained in the islets of Langerhans, with the highest expression is 
in b cells of the pancreas. ZnT8A measurements simultaneously with GADA, IA-2A and IAA achieve rates of 98% detection 
for onset level of autoimmune diabetes. Presence of antibodies in T2D also shows the potential serious complications 
compared with T2D without antibodies. The combination of GADA, IA-2A and ZnT8A can be suggested as the most powerful 
and cost-effective diagnostic approach in patients with T1D. 
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Introduction
Diabetes mellitus is a disease characterized by hyperglycemia 
and is caused by absolute or relative insulin deficiency, 
sometimes associated with insulin resistance.1,2 Diabetes 
also known as a complex chronic disease that requires 
ongoing medical care with a strategy of multifactorial risk 
reduction beyond glycemic control.3 Based on American 
Diabetes Association (ADA), diabetes can be classified 
into the following general categories: type 1 diabetes 
(T1D), type 2 diabetes (T2D), gestational diabetes mellitus 
(GDM), specific types of diabetes due to other causes, e.g., 
monogenic diabetes syndromes, diseases of the exocrine 
pancreas, and drug- or chemical-induced diabetes.4
 T1D known as juvenile diabetes, caused by a chronic 
autoimmune disorder where targeted  immune response by 
both T and B cells.5 The pancreatic β-cells that produce 
insulin are the target of immune attack by both T and B 
cells leading to destruction of insulin production in the 
islets of the pancreas.6,7 T1D is an autoimmune disease that 
occurs when the body can no longer produce insulin due to 
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the destruction of the insulin producing β-cells of the islet of 
Langerhans in the pancreas.8
 Autoimmunity is a complex multifactorial process 
which are defined by the loss of self-tolerance and chronic 
excess of reactivity B and T cells due to release of the 
danger signals. The pathogenesis are caused by multiple 
factors, both genetic and environment. The involvement 
of autoimmune indicates by the persistent presence of 
the circulating autoantibodies or self-reactive T cells, the 
lymphocytic infiltration in the target organs.9,10 
 Autoantibodies can be formed due to the breakdown 
in tolerance. For autoantibodies to appear, the autoantigen 
must become available to the immune system and the 
immunization event occurred. Immunization that results in 
an immunoglobulin (Ig)G autoantibody response requires 
switching of B-lymphocyte class, and therefore cluster of 
differentiation (CD)4 T cells must be involved in addition to 
naive mature B cells.11 
 The autoantibodies can be detected before and at 
time of clinical diagnosis of disease. Although the role of 
autoantibodies in the pathogenesis is debated, their presence 
indicates a dysregulation of the humoral immune response.10 
Mechanisms regulating autoantibodies in T1D are not well 
understood as well. Other than insulin and carboxypeptidase 
H, all islet antigens are intracellular and are not normally 
secreted or expressed on the surface of the cell. The release 
of intracellular antigens is possibly the result of cell 
mediated autoimmune damage to cells, which permits such 
otherwise sequestered self antigens access to naive mature 
B lymphocytes and naive CD4 T cells. However, if the cells 
were to die, β-cells death might have then led to subsequent 
islet autoantigen immunization.12
  The pancreatic islets respond to insulin resistance by 
enhancing their cell mass and insulin secretory activity. 
However, when the functional expansion of islet β-cells 
fails to compensate for the degree of insulin resistance, 
insulin deficiency resulted and ultimately T2D develop.13
 Obesity is by far the main underlying factor causing 
T2D and its pathological potential lies in obesity-associated 
insulin resistance, activation of innate immunity and chronic 
low-grade inflammation.14,15 Obesity and chronic overfeeding 
lead to metabolic and adipocyte stress. Stressed adipocytes 
secrete pro-inflammatory cytokines such as interleukin (IL)-
1β, IL-6 or tumor necrosis factor (TNF)-α, which activate 
T cells, B cells and macrophages. Chronic inflammatory 
state in T2D is characterized by an increased production of 
cytokines, most notably IL-1β, which destroy β cells. When 
tissue inflammation induced, tissue destruction occurs, 'self' 
antigens, which are generally not accessible to T cells, can be 
released from the affected tissues and promote autoimmune 
activation. Hyperglycaemia contributes to the increased of 
several β-cell antigens, such as glutamid acid decarboxylase 
antibody (GADA), increasing the vulnerability of β cells 
to autoantibodies such as anti-GAD, the most frequently 
detected autoantibodies in phenotypic T2D.9 Persistent 
GADA can be occured between latent autoimmune diabetes 
in adult (LADA) and T2D.16,17
 The 4 major autoantibodies are islet-cell cytoplasmic 
autoantibodies (ICA), GADA, islet antigen-2 antibody 
(IA-2A) and insulin autoantibodies (IAA). ZnT8 islet 
autoantibody (ZnT8A) may further improve the value of islet 
autoantibody testing.18-20 The presence of autoantibodies 
against islet cells and the enzymes of pancreatic b islet cells 
can also be used as predictors of the onset of T1D in patients 
with LADA.21 
ICA
The availability of an epifluorescent light source was the 
technical breakthrough that permitted the development 
of indirect-immune-fluorescent (IIF) technique for 
ICA. Antibodies react with all endocrine islet cells.22 
The lowest significant positive for ICA is 10 Juvenile 
Diabetes Foundation (JDF) units. ICA react against a 
sialoglycoconjugate, an insulinoma associated autoantigen, 
and GAD. ICA are the most difficult islet autoantibodies to 
measure because ICA assays are subject to variations in the 
pancreatic tissue and technical aspects including antibody 
conjugation, incubation time, humidity, and biological 
scientist interpretation.12,20,22
GADA
GADA first identified through immunoprecipitation islet cell 
proteins labeled with 35S Methionin dissolved in the serum 
of patients with T1D.17 GAD is an enzyme that catalyzes 
the formation of gamma-amino butyric acid (GABA) from 
glutamate.19 GABA is an major inhibitor neurotransmiter 
in the brain, it is stored in synaptic microvesicel. In the 
pancreatic islet b cell GABA is also produced in large number, 
stored in synaptic-like microvesicle, and have a paracrine or 
autocrine activity in pancreatic islet cells. GABA activity 
mechanisms in pancreatic b cells are not fully understood.20 
GABA is a ligand for a GABAergic receptor that located on 
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the surface of cell membrane. GABA receptor have three 
types of receptors,  GABA-A  and GABA-C receptors, 
which are the receptors of ligand-gated Cl- ion channels, and 
GABA-B receptor is a ligand gated Ca
2
+/K+ ion channel. 
GABA-A  receptors (GABAAR)  and GABA-B Receptors 
(GABABR) are expressed on the surface of pancreatic b 
cells.22 Activation of GABA receptors in pancreatic b cells 
resulting in an increased release of insulin, which has a 
protective and regenerative effect on pancreatic b cells, and 
decreases apoptosis of pancreatic b cells.23 
 GAD has two isoforms, 67-Kd GAD (GAD67) and 
GAD65 Kd (GAD65).4 GAD67 is an enzyme that is always 
active and responsible in the basal concentration of GABA. 
GAD67 is encoded by genes located at chromosome 2q31 
and is mostly found in neuronal cells. While GAD65 
active transient, where activation depending on the needs 
extra GABA, GAD65 are encoded by genes located at 
chromosome 10p11. GAD65 has 585 amino acids and at 
most been recorded on pancreatic b cells.24 
 The presence of GAD65 antibodies causes pancreatic 
b islet cells can not produce insulin adequately.25 In patients 
with T1D, more than 90% found one or more antibodies 
directed against b islet cells of the pancreas, one of which is 
the GAD65 antibodies.21
IA-2A
Most patients with T1D have antibodies against tryptic 
fragments of 40- and/or 37-kDa derived from islet cell 
membrane protein which is not yet known and is a different 
protein from GAD.26 The protein is IA-2, previously 
known as ICA-512. IA-2 are the main targets of islet cell 
autoantibodies. Protein is found also in these nerve tissue, 
encoded by a gene located at chromosome 2q35.27 This 
gene encodes a 979 amino acid, enzymatic trans-membrane 
protein that is inactive, and the protein tyrosine phosphatase 
(PTP)-like-molecule. This antigen has no enzymatic 
activity for several substitutions in highly conserved sites 
and expressed mainly in neuroendocrine cells such as the 
central nervous system as well as in the islets of Langerhans 
cells. The residue intracellular antigen is anchored on the 
membrane of the insulin secretory granule, and the dominant 
antibody will attack the intracellular domain (amino acids 
601-979) and this only occurs when there is a damage cells. 
The function of the antigen is not known with certainty. 
Experiments on mice showed the role of IA-2 in insulin 
secretion.28
 PTP-like molecule called IA-2β or phogrine 
resemblance in many respects to IA-2, especially in the 
location and the intracellular domain (74% identical). 
Immunoprecipitation of cell lysates insulinoma with T1D 
sera produce a 64kDa protein, and after treatment with 
trypsin, fragments of 37 and 40 kDa can be resulted. 
Additional studies revealed that IA-2 is the precursor of the 
40kDa and IA-2β of the 37kDa molecule.29
 IA-2A can be the complement of GADA test, since 
more than 90% of children have antibodies to at least one 
of these proteins at diabetes onset. IA-2 and GAD make 
the predominant, but not exclusive, contribution to ICA-
reactivity. The presence of IA-2A in particular, which is 
often associated with other antibodies, confers a higher risk 
of rapid progression toward clinical onset than multiple 
antibodies.30 It is suggested that the production of IA-2A 
coincides with a critical switch in disease progression, 
where the intracellular domain of IA-2 may only become 
visible to the immune system at the outer cell surface in the 
case of b cell damage or dysfunction.31
IAA
IAA may appear in the beginning of life, IAA is the first 
autoantibodies that often arise during the prediabetic phase 
and  they  are  usually detected in young children in diagnosis 
of T1D, so that it can be used to predict the onset of T1D.30-33 
But not all IAA will develop into T1D. Children who do not 
develop autoantibodies to several b cell antigen, rarely will 
develop into T1D. For the initial risk assessment, therefore, 
it would be useful to identify children with IAA-positive 
who will develop to diabetes.32
 Knowing affinity can be identified IAA-positive 
children who are more likely to become diabetic. Studies 
have been conducted to determine if an affinity useful as a 
marker of risk stratification of T1D in IAA-positive children 
from the general population. IAA affinity was determined 
by competitive binding with increased concentrations of 125I 
insulin and insulin cool with cold proinsulin in sera from 46 
IAA-positive children identified in Karlsburg Risk Type 1 
Diabetes Study of normal school children population in the 
north-east German. The result showed higher affinity IAA on 
24 children who develop autoantibodies island or diabetes 
compared to 22 children who did not develop autoantibodies 
island or diabetes. In conclusion IAA affinity measurements 
provide strong identification of IAA and associated with a 
higher risk of diabetes. Research shows high-affinity IAA 
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and proinsulin reactivity characteristics of the IAA in first-
degree relatives who developed autoantibodies islet and 
T1D.32
 IAA level from time to time is not affected by oral 
insulin. The level of autoantibodies is only one aspect of the 
autoimmune response. Factors such as IgG subtypes, IAA 
affinity and T cell response to insulin are also important 
factors. For that we need further evaluation.33
 IAA level inversely correlated with age. The highest 
level seen in diabetic children under the age of 5 years. In 
patients with T1D, insulin antibody comprises mainly IgG1 
antibodies, whereas IgG3 antibodies were more common 
prior to the initiation of exogenous insulin. In children of 
parents with T1D, IgG1 was mostly detected while IgG4 
was detected in some cases. The presence of IgG4 was not 
associated with protection from clinical disease. There are 
some heterogeneity in the response of IAA isotype, but 
mostly the response IgG1-IAA is the first to appear, while 
IgG4-IAA show up late.34
ZnT8A
In addition to ICA and biochemical autoantibodies (BAA) 
to insulin IAA, GAD65A, and IA-2A, ZnT8A has recently 
been found to predict T1D.35-41 ZnT8 is contained in the 
islets of Langerhans, with the highest expression is in b 
cells of the pancreas. ZnT8A expression may not occur until 
damage to β cells enough to make ZnT8 immunological 
visible.21,28 ZnT8 is a trans-membrane protein 369 amino 
acids, encoded by the SLC30A8 at chromosome 8q14.11. 
ZnT8 contains six trans-membrane domain, amino and 
carboxy-terminal cytoplasmic tail. ZnT8 more specifically 
expressed in insulin secretion granules, containing than 
GAD65 and IA-2. ZnT8 serves to maintain intracellular zinc 
homeostasis, which modulates insulin biosynthesis process, 
storage, and secretion. Therefore, antibodies to ZnT8 may 
affect some of the important processes.39-43
 More than 60% of new cases were diagnosed positive 
for ZnT8A, and 4% of the cases were positive only on 
ZnT8A. ZnT8A was detected in about 70% of patients at 
diabetes onset.37 ZnT8A then can be used as markers and 
prediction of T1D. The percentage of newly diagnosed 
cases of T1D and positive ZnT8A (according to the size 
titer) was positively correlated with older age at diagnosis 
of T1D in children.35 ZnT8A prevalence tends to be higher 
in children than teenagers, but the difference was not 
statistically significant. The relationship between ZnT8A 
and actual age controversial because on the Chinese 
children, the prevalence ZnT8A lower in older patients, 
while in a very large study in Finland, ZnT8A positivity was 
associated with older age at diagnosis. Prevalence ZnT8A 
remained substantially stable in patients up to four years of 
clinical diagnosis, but then showed a significant decrease, 
and ZnT8A finally fixed at about 34% of 5 years-diagnosed 
patients.43
 The ZnT8A are appear between 60-80% of Caucasian 
patients with T1D at onset and together with IAA, GAD65, 
and IA-2A, can confirm the diagnosis of autoimmune 
diabetes in more 94% of subjects. Genetic risk in first-degree 
relatives T1D cases followed prospectively, ZnT8A appear 
at an average age of 3-4 years and generally persist until the 
onset of clinical disease.44 ZnT8A are positively detected 
in 530 children (73%). Positive for ZnT8A at diagnosis 
appears to reflect a more aggressive disease process before 
and after the diagnosis.38
 In families with T1D were positive for one or more 
of the standards relating to diabetes BAA (IAA, GAD65A, 
or IA-2A). ZnT8A test can be useful information about 
the risk of diabetes. A direct link between the number of 
positive autoantibodies and the risk of diabetes, that ZnT8A 
gradually adding risk compared to standard BAA and ICA.36
 ZnT8A measurements simultaneously with GADA, 
IA-2A and IAA achieve rates of 98% detection for onset 
level of autoimmune diabetes. This approach is needed 
to detect pre-diabetes in children. ZnT8A associated with 
other autoantibodies, can improve diagnostic performance 
as a whole and a positive predictive value of laboratory.43 
When introducing ZnT8A as a complement of the current 
biomarker, the overall diagnostic performance significantly 
improved the serological test. The combination of GADA, 
IA-2A and ZnT8A as the most powerful and cost-effective 
diagnostic approach in patients with T1D.43
The relation between autoantibody and T2D
Islet autoimmunity may be more common than 
previously thought and may be an important contributor 
to the progressive decline in β-cells function observed 
in phenotypic T2D patient.10 The identification of these 
autoantibodies in elderly patients with slowly progressive 
manifestation of diabetes led to the introduction of a distinct 
clinical entity termed LADA, which combines features 
of both T1D and T2D. The autoantibody cluster differs 
in patients with LADA from patients with T1D, but their 
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presence indicates steady progression towards β-cell death 
and subsequent need for initiation of insulin treatment in a 
shorter period of time compared to autoantibody-negative 
T2D patients. Autoimmune aspects in T2D are not solely 
restricted to autoantibodies and thus LADA. They include 
the self-reactive T cells or defects in regulatory T cells 
(Tregs), which have been detected in autoantibody-negative 
T2D patients as well.9
 T2D is the consequence of a defective insulin 
response to increased insulin needs that result from insulin 
resistance, but evolve with time to progressive loss of 
insulin secretion. The respective part of a functional defect 
and that of a decrease in the β-cells mass remains an open 
issue in T2D.44 Autoimmune diabetes may masquerade as 
T2D in adults as well. It has been known since the early 
days of ICA measurements that diabetic patients who failed 
oral hypoglycemic agents often had ICAs. Many features of 
insulin release and metabolic phenotypes in LADA patients 
distinguish them from both T1D and T2D patients.31 It is 
also known that  islet autoimmunity progresses more rapidly 
in the context of “overload” of the β-cell due to increased 
insulin resistance.45 However, the type of autoantibody in 
TID and T2D are the same. The antibody in patients with 
T2D make consideration whether the future will require 
exogenous insulin as in T1D.46 Presence of antibodies in T2D 
also shows the potential serious complications compared 
with T2D without antibodies. In addition, adiposity is a risk 
factor in the development of autoimmune T2D.47
Autoantibodies in GDM
The prevalence of gestational diabetes in the world is 
about 7% of the entire population of pregnant women in 
the world.48 Some of them have such antibodies associated 
T1D.49 Pregnancy itself is a risk of the outbreak of TID. 
Where, the pregnancy is the combination of physiologic 
changes of pregnancy-related in metabolize glucose 
and immune system regulation.50-51 Women with GDM 
autoimmune generally do not have such characteristic in 
T2D, they typically do not obesity, occurs at a young age 
(<30 years).45 They looks like be in need of treatment with 
insulin beyond diet modification.49
 Antibodies against GAD and IA-2 are antibodies most 
widely reported. Then antibodies against ZnT8 also found 
in some women with GDM.52 Several studies have reported 
that the frequency of antibody ZnT8 almost as high as GAD 
antibodies in clinical onset T1D, but often in combination 
with GAD and/or IA-2 antibodies.37 Autoimmune antibody 
screening is recommended in women who are at risk of 
GDM. It is certainly aimed to anticipate the development of 
GDM, whether toward T2D or T1D.53 
Conclusion
The assumption that the pathogenesis of T2D also 
encompasses autoimmune aspects is recognized increasingly, 
based on the presence of circulating autoantibodies against 
β cells, self-reactive T cells, also on the glucose-lowering 
efficacy of some immunomodulatory therapies in T2D. The 
combination of GADA, IA-2A and ZnT8A can be suggested 
as the most powerful and cost-effective diagnostic approach 
in patients with T1D.
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